Retinal Thinning as a Marker of Disease Severity in Progressive Supranuclear Palsy
- Author:
Yueting CHEN
1
;
Haotian WANG
;
Bo WANG
;
Wenbo LI
;
Panpan YE
;
Wen XU
;
Peng LIU
;
Xinhui CHEN
;
Zhidong CEN
;
Zhiyuan OUYANG
;
Sheng WU
;
Xiaofeng DOU
;
Yi LIAO
;
Hong ZHANG
;
Mei TIAN
;
Wei LUO
Author Information
- Publication Type:1
- From:Journal of Movement Disorders 2024;17(1):55-63
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Objective:Progressive supranuclear palsy (PSP) involves a variety of visual symptoms that are thought to be partially caused by structural abnormalities of the retina. However, the relationship between retinal structural changes, disease severity, and intracranial alterations remains unknown. We investigated distinct retinal thinning patterns and their relationship with clinical severity and intracranial alterations in a PSP cohort.
Methods:We enrolled 19 patients with PSP (38 eyes) and 20 age-matched healthy controls (40 eyes). All of the participants underwent peripapillary and macular optical coherence tomography. Brain 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane (11C-CFT) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography imaging were also performed in patients with PSP. We investigated the association between retinal thickness changes and clinical features, striatal dopamine transporter availability, and cerebral glucose metabolism.
Results:The peripapillary retinal nerve fiber layer (pRNFL) and macula were significantly thinner in patients with PSP than in controls. The thickness of the superior sector of the pRNFL demonstrated a significant negative relationship with the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III and Hoehn and Yahr staging scale scores. A significant negative correlation was found between outer inferior macular thickness and disease duration. Outer temporal macular thickness was positively correlated with Montreal Cognitive Assessment scores. In PSP, lower outer temporal macular thickness was also positively correlated with decreased dopamine transporter binding in the caudate.
Conclusion:The pRNFL and macular thinning may be candidate markers for monitoring disease severity. Additionally, macular thinning may be an in vivo indicator of nigrostriatal dopaminergic cell degeneration in PSP patients.
